Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 ...

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to ...

You're Probably Not Washing Your Hair Enough—Doctors Reveal How Often You Really Should

When it comes to hair washing, there is no one-size-fits-all solution. How often you need to cleanse your strands depends on ...

Predictive model shows moderate performance for psoriasis relapse risk

A predictive model for psoriasis relapse risk demonstrates moderate performance, according to a study published online April ...
pharmaphorum

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis. The US regulator has approved icotrokinra under the ...

Sulfate-Free Vs Regular Shampoo: Which Is Better?

Neither sulfate-free nor regular shampoo is universally better. The right choice depends on your scalp type, hair texture, ...
Medscape

Psoriasis: Latest

Alert Pediatric Plaque Psoriasis Treatment Set to Expand in Europe European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in ...